logo
Cyclo Olefin Polymer (COP) Films Market to Reach $2.6 Billion by 2034, Fueled by Rising Demand in Medical, Packaging and Electronics Sectors

Cyclo Olefin Polymer (COP) Films Market to Reach $2.6 Billion by 2034, Fueled by Rising Demand in Medical, Packaging and Electronics Sectors

Yahoo27-05-2025

Cyclo Olefin Polymer (COP) Films Market Outlook (2025–2034)
Luton, Bedfordshire, United Kingdom, May 27, 2025 (GLOBE NEWSWIRE) -- Market Overview
The Cyclo Olefin Polymer (COP) films market is projected to reach a value of approximately $1.5 billion in 2024, driven by increasing demand in the medical, packaging, and electronics sectors. During the forecast period from 2025 to 2034, the market is expected to show robust growth, with a projected market value of $2.6 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of around 6.2%.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/64794/cyclo-olefin-polymer-cop-films-market#request-a-sample
Key trends influencing the market include rising demand for lightweight and high-performance materials, advancements in polymerization technology, and a significant push for sustainable packaging solutions. Moreover, the increasing uptake of COP films in medical technology, particularly in drug delivery systems and diagnostic devices, is anticipated to bolster market growth.COP films, known for their optical clarity, biocompatibility, and thermal resistance, are increasingly replacing traditional polymers in critical applications. Their role in medical diagnostics, smart packaging, and display technologies is expected to be instrumental in market evolution.
Market Segmentation
By Product Type
Transparent Films
Opaque Films
By Application
Packaging
Medical
Electronics
By End User
Pharmaceuticals
Consumer Goods
Electronics Manufacturers
By Technology
Injection Molding
Film Extrusion
By Distribution Channel
Direct Sales
Online Sales
Material Type Analysis
Cyclo Olefin Polymer (COP)
COP is a type of amorphous polymer derived from norbornene and other cyclic monomers via ring-opening metathesis polymerization (ROMP). Its unique molecular structure results in superior performance characteristics, making it the leading material type in this market.
Key Properties & Advantages:
High Optical Clarity: Near glass-like transparency, essential for optical and medical applications.
Low Moisture Absorption: Maintains dimensional stability in humid conditions.
Excellent Barrier Properties: Superior resistance to moisture, oxygen, and other gases—ideal for pharmaceutical packaging.
Biocompatibility: Safe for direct contact with human tissue and fluids, making it FDA and USP Class VI compliant.
Thermal Stability: Maintains structural integrity under sterilization (gamma, steam, or ethylene oxide).
Applications:
Medical Diagnostics: Used in microfluidic devices, diagnostic cassettes, and bio-chips.
Optical Components: Employed in lenses, light guides, and high-end displays.
Sterile Packaging: Ideal for syringe barrels, blister packs, and single-use medical devices.
Browse full Report - https://exactitudeconsultancy.com/reports/64794/cyclo-olefin-polymer-cop-films-market Cyclic Olefin Copolymer (COC)
COC is a copolymer formed by combining ethylene with cyclic olefins. It shares many properties with COP but offers unique advantages in specific applications.
Key Properties & Advantages:
Higher Thermal Resistance: Withstands temperatures up to 170°C, suitable for hot-fill and sterilization processes.
High Rigidity and Stiffness: Offers a robust alternative to polycarbonate and polystyrene.
Low Extractables: Important for sensitive drug formulations.
Recyclability: Compatible with mono-material recycling streams, making it attractive for sustainable packaging.
Applications:
Sustainable Packaging: Used in recyclable pharmaceutical blister packs and food trays.
Medical Containers: Vials and ampoules with minimal interaction with drug contents.
High-Barrier Films: For flexible pouches and barrier laminates in food packaging.
End-Use Industry Insights
1. Packaging (Largest Segment)
The packaging sector is the primary driver of demand for COP and COC films, accounting for the largest revenue share in the market.
Growth Drivers:
Lightweight & Transparency: Brands prefer thinner, clearer films for modern, minimalist packaging designs.
Shelf Life Extension: COP films' barrier properties help preserve pharmaceuticals, perishable foods, and sensitive electronics.
Regulatory Push: Strict regulations in the EU and North America are promoting high-performance, non-toxic packaging materials.
Applications:
Pharmaceutical Blisters
Food-grade Pouches & Wraps
Consumer Electronics Packaging
Sterile Barrier Systems
2. Medical Devices (Fastest-Growing Segment)
COP films are revolutionizing the medical industry due to their safety and performance. The segment is projected to grow at the highest CAGR during the forecast period.
Key Advantages:
Biocompatibility: Meets USP Class VI and ISO 10993 requirements.
Chemical Inertness: No reaction with most acids, bases, and solvents used in drug formulations.
Sterilization Compatibility: Maintains integrity under autoclaving, gamma irradiation, and EtO processes.
Applications:
Pre-filled Syringes & IV Containers
Diagnostic Kits & Lab-on-a-Chip Devices
Drug Delivery Systems
Catheter Packaging
3. Optical Applications
The optical and optoelectronics sector is increasingly adopting COP films for their exceptional light transmission and dimensional stability.
Market Trends:
AR/VR Technologies: Demand for lightweight, distortion-free lenses in immersive headsets.
Smart Displays: COP films are used in OLED and LCD screen manufacturing for their low birefringence and high refractive index.
Imaging Sensors: Optical-grade COP films support precision manufacturing of light-guiding components.
Applications:
Camera Lens Covers
Virtual Reality Goggles
Light Diffusers in Smart Lighting
Projection Film Screens
Thickness Analysis
Thin Films (<100 Microns)
Market Share: Dominates in flexible packaging and medical diagnostics due to reduced material usage and superior performance.
Benefits:
Cost Efficiency: Lower material cost and faster production throughput.
Flexibility & Conformability: Suitable for overwraps and pouches that must bend or fold without cracking.
Lightweight: Helps reduce shipping costs and carbon footprint.
Use Cases:
Flexible Food & Drug Packaging
Diagnostic Strip Laminates
Disposable Medical Device Covers
Thick Films (≥100 Microns)
Market Use: Preferred in rigid or semi-rigid packaging, optical applications, and components requiring dimensional strength.
Benefits:
Durability & Strength: Provides protection for high-value or fragile contents.
Thermoformability: Used to mold rigid containers or trays with high clarity.
Impact Resistance: Used in protective and transport packaging.
Use Cases:
Blister Packs for High-End Pharmaceuticals
Rigid Medical Device Enclosures
Optical Film Sheets in Electronics
Multi-layer Laminates for Durable Packaging
Buy Now : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=64794
Application Insights
1. Flexible Packaging (Dominant Segment)
Flexible packaging is the largest application segment for COP films due to their lightweight, transparency, and excellent barrier properties.
Market Drivers:
Convenience & Portability: Consumer preference for resealable, easy-to-open, and lightweight packaging formats.
Shelf-Life Extension: COP films offer high oxygen and moisture barrier performance, essential for preserving food and pharmaceuticals.
Customization: Easy to print and laminate, allowing for high-quality brand graphics and QR code integration.
Key Applications:
Pharmaceutical Sachets & Strip Packs
Food Packaging (snack pouches, meat wrappers, dairy films)
Electronics Components Packaging
Cosmetics & Personal Care Pouches
Trends:
Rise in e-commerce packaging, especially for pharmaceuticals and electronics.
Use of monomaterial recyclable flexible laminates to meet sustainability goals.
2. Rigid Packaging
Rigid COP films are used in premium product packaging, where clarity, stiffness, and durability are critical.
Market Drivers:
Product Protection: Suitable for fragile or high-value items due to impact resistance.
Visual Appeal: Crystal-clear visibility improves shelf impact and perceived value.
Thermoformability: Used for forming structured trays and blisters.
Key Applications:
Pharmaceutical Blister Packs
Medical Device Trays
Consumer Electronics Clamshell Packaging
Luxury Cosmetic Cases
Trends:
Growing demand in high-end nutraceuticals and clinical diagnostics.
Development of sustainable rigid packaging formats using recyclable COC/COP blends.
3. Labels & Stickers
COP films are increasingly used in labels and stickers, particularly for high-end branding and smart packaging.
Market Drivers:
Aesthetic Quality: High clarity and gloss for premium label finishes.
Durability: Resistance to water, chemicals, and UV makes them suitable for outdoor and refrigerated products.
Technological Integration: Compatible with RFID tags, anti-counterfeit features, and thermal printing.
Key Applications:
Pharmaceutical & Healthcare Product Labels
Luxury Beverage & Cosmetic Labels
Electronic Product Labels
Security Stickers and Holograms
Trends:
Adoption of smart labels with traceability features.
Growing demand from personalized packaging solutions in FMCG.
4. Medical Packaging
Medical packaging represents a critical and rapidly expanding segment, driven by safety standards and sterility needs.
Market Drivers:
Biocompatibility & Sterility: COP films meet stringent standards for direct-contact applications.
Chemical Resistance: Ensures no interaction with drugs or sterilizing agents.
Global Healthcare Expansion: Rising demand for pre-filled syringes, IV containers, and diagnostic kits.
Key Applications:
Pre-filled Syringe Barrels
Diagnostic Device Blisters
Surgical Kit Packaging
Sterile Barrier Systems
Trends:
Increase in home-care diagnostics and point-of-care devices post-COVID.
Regulatory emphasis on tamper-evident and single-use medical packaging.
Regional Analysis
1.Asia-Pacific (Leading Region – 45% Market Share in 2024)
Market Characteristics:
Strong Manufacturing Base: Extensive production capabilities in China, Japan, South Korea, and India.
Growing Middle-Class Population: Drives consumption of electronics, packaged foods, and healthcare products.
Electronics Hub: South Korea and Japan are at the forefront of AR/VR, displays, and sensor tech that rely on COP films.
Growth Factors:
Rise in domestic diagnostics and pharma production.
Strong government support for semiconductor and medical manufacturing sectors.
Key Countries:
China: Largest contributor, especially in flexible packaging and healthcare.
Japan: Innovation hub for optical and medical-grade COP films.
South Korea: Rapid advancements in electronics and OLED technology.
2.North America (25% Market Share, 7% CAGR Through 2034)
Market Characteristics:
Sustainability Focus: Push for recyclable and bio-compatible materials.
Advanced Healthcare Infrastructure: High demand for sterile, single-use medical packaging.
Consumer Preference for Innovation: Brands seeking premium packaging and smart labeling.
Growth Factors:
Adoption of COP-based blister packs over PVC due to safety and recyclability.
Growth in biotech and specialty pharma sectors.
Key Markets:
U.S.: Dominates the region with FDA approval requirements favoring COP in drug packaging.
Canada: Emerging interest in sustainable packaging innovations.
3.Europe (20% Market Share, 6% CAGR)
Market Characteristics:
Stringent Environmental Regulations: Ban on PVC and single-use plastics promoting alternatives like COP.
Technological Advancements: Strong R&D focus on automotive, optics, and healthcare.
Circular Economy Push: Encouraging adoption of recyclable COP/COC packaging.
Growth Factors:
Strong demand from Germany, France, and Nordic countries for healthcare and electronics packaging.
Innovation-driven market: Active development of advanced diagnostic and imaging solutions.
Key Industries:
Automotive sensors, AR headsets, and diagnostics.
EU Green Deal accelerates shift to sustainable packaging materials.
4.Latin America, Middle East & Africa (Emerging Markets)
Market Characteristics:
Emerging Consumer Base: Growing demand for modern packaging in consumer goods and healthcare.
Healthcare Expansion: Gradual rollout of universal healthcare services fueling demand for medical packaging.
Industrial Packaging: Increase in demand for protective and durable packaging solutions in chemicals and electronics.
Growth Challenges:
Economic Instability: Currency fluctuations and political instability may hinder investments.
Infrastructure Gaps: Limited cold chain and medical supply networks slow adoption.
Key Opportunities:
Brazil and Mexico: Driving adoption in Latin America.
UAE and Saudi Arabia: Investing in healthcare modernization and smart packaging technologies.
Market Dynamics
Growth Drivers
Increasing adoption in medical diagnostics and pharmaceutical packaging.
Rising demand for lightweight and transparent materials in consumer goods and electronics.
Technological advancements in polymerization and extrusion techniques.
Regulatory push for safe and sustainable materials.
Market Challenges
Volatile raw material prices, particularly cycloolefin monomers.
Competition from low-cost alternatives like polyethylene and polypropylene.
Regulatory hurdles related to material disposal and compliance.
Potential supply chain disruptions due to global uncertainties.
Growth Opportunities
Expansion of sustainable packaging aligned with circular economy goals.
Increasing adoption in smart packaging, biopharmaceuticals, and AR/VR devices.
Collaborative product development between COP manufacturers and end-users.
Opportunities in developing economies through government-backed sustainability initiatives.
Competitive Landscape
Key Players
Mitsui Chemicals
Dow Chemical Company
SABIC
Toray Industries
Kuraray Co., Ltd.
Zeon Corporation
INEOS
3M Company
Fuxin Hualong New Materials
Polyplastics Co., Ltd.
DIC Corporation
Goodfellow
Aunilex
KONKA Group
Recent Developments
1.Mitsui Chemicals – Strategic Partnership (March 2023)
Overview: Mitsui Chemicals announced a collaboration with a leading electronics manufacturer to co-develop next-generation COP films for OLED displays.
Key Details:
Purpose: Enhance the performance and reliability of OLED panels by utilizing the superior optical and barrier properties of COP films.
Focus Areas:
Improved light transmittance and thermal resistance for OLED layers.
Development of ultra-thin, flexible substrates suitable for foldable and rollable displays.
Strategic Goals:
Position COP films as the preferred material in high-end consumer electronics (smartphones, tablets, AR/VR headsets).
Expand market penetration in Asia-Pacific, especially South Korea and Japan, where OLED manufacturing is concentrated.
Implications:
Strengthens Mitsui Chemicals' role in advanced display technologies.
Promotes cross-industry innovation between materials science and electronics.
May lead to patent developments and expanded licensing opportunities.
2. Dow Chemical Company – Eco-Friendly Product Launch (February 2023)
Overview: Dow Chemical introduced a new line of eco-conscious COP films engineered for sustainable packaging applications.
Key Details:
Features of the New Product Line:
Recyclable mono-material composition, enabling easier integration into circular economy models.
Enhanced barrier protection while reducing the carbon footprint.
Compatible with existing flexible packaging machinery, ensuring seamless industrial adoption.
Market Focus:
Targeted at FMCG, food & beverage, and pharmaceutical companies seeking sustainable solutions.
Complies with global regulatory trends such as the EU Plastic Strategy and U.S. Extended Producer Responsibility (EPR) policies.
Strategic Motivation:
Address growing consumer concerns over plastic waste and corporate sustainability mandates.
Strengthen Dow's product portfolio under the 'Sustainable Packaging' banner.
Implications:
Boosts brand reputation in environmentally responsible innovation.
Likely to gain traction among multinational CPG brands aiming for plastic reduction targets.
Encourages broader industry shift towards green alternatives in polymer films.
This report is also available in the following languages : Japanese (電子戦システム市場), Korean (전자전 시스템 시장), Chinese (电子战系统市场), French (Marché des systèmes de guerre électronique), German (Markt für elektronische Kriegsführungssysteme), and Italian (Mercato dei sistemi di guerra elettronica), etc.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/64794/cyclo-olefin-polymer-cop-films-market#request-a-sample
More Related Reports:
Maleic Anhydride Graft Polymer Market
The maleic anhydride graft polymer market is valued at approximately $1.2 billion, driven by its diverse applications across industries such as automotive, packaging, and construction. The market is forecasted to reach $2.4 billion by 2034, reflecting a robust growth trajectory. This equates to a compound annual growth rate (CAGR) of around 7.2% over the 2025–2034 period.
https://exactitudeconsultancy.com/reports/64782/maleic-anhydride-graft-polymer-market
Redispersible Polymer Powder Market
The global redispersible polymer powder market size was valued at USD 1.76 billion in 2020, and projected to reach USD 2.92 billion by 2029, with a CAGR of 5.78% from 2022 to 2029.
https://exactitudeconsultancy.com/reports/64684/redispersible-polymer-powder-market
Dissolvable Metal Frac Plugs Market
The global dissolvable metal frac plugs market is projected to reach a valuation of approximately $620 million in 2024. The market is anticipated to expand at a robust pace, with a projected compound annual growth rate (CAGR) of 12.5% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/64683/dissolvable-metal-frac-plugs-market
Fiber Reinforced Polymer FRP Composites Market
The global Fiber Reinforced Polymer (FRP) Composites market is valued at approximately $85 billion in 2024, with substantial growth anticipated through 2034. Projections suggest the market will reach around $130 billion by the end of the forecast period, marking a Compound Annual Growth Rate (CAGR) of about 5.5%.
https://exactitudeconsultancy.com/reports/64666/fiber-reinforced-polymer-frp-composites-market
Asphalt Additives and Modifiers Market
The global asphalt additives and modifiers market is poised to reach an estimated value of $6 billion in 2024, with a robust projected growth trajectory signaling an increase to approximately $10 billion by 2034. This translates to a compound annual growth rate (CAGR) of around 5.2% during the forecast period of 2025–2034.
https://exactitudeconsultancy.com/reports/64564/global-asphalt-additives-and-modifiers-market
Gravure Printing Plates Market
The global gravure printing plates market is valued at approximately USD 1.6 billion in 2024. Forecasts indicate a robust growth trajectory, with market value expected to reach around USD 2.5 billion by 2034, driven by rising demand from packaging, publication, and decorative printing sectors. The Compound Annual Growth Rate (CAGR) for this period is projected at 5.0%, reflecting strong industry momentum.
https://exactitudeconsultancy.com/reports/64536/global-gravure-printing-plates-market
Plant Based Hemostat Powder Market
The global plant-based hemostat powder market is valued at approximately $1.2 billion in 2024, driven by the increasing demand for minimally invasive surgical procedures and a growing preference for sustainable medical solutions. The market is projected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.1% between 2025 and 2034.
https://exactitudeconsultancy.com/reports/64365/global-plant-based-hemostat-powder-market
Textile Fluorine Free Water Repellent Market
The global textile fluorine-free water repellent market is valued at approximately $1.2 billion in 2024 and is projected to reach $2.3 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 7.1% over the forecast period.
https://exactitudeconsultancy.com/reports/64359/global-textile-fluorine-free-water-repellent-market
Fluoropolymer Processing Aid Market
The global fluoropolymer processing aid market is valued at approximately $1.8 billion in 2024, driven by the increasing demand for high-performance materials in various applications, including automotive, electronics, and packaging industries. As manufacturers emphasize efficiency and sustainability, the adoption of fluoropolymer processing aids is projected to grow, leading to a market value of around $3.1 billion by 2034.
https://exactitudeconsultancy.com/reports/64275/global-fluoropolymer-processing-aid-market
Polymer Modified Asphalt Market
The global polymer modified asphalt market is valued at approximately $12.5 billion in 2024 and is projected to reach around $22 billion by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/64249/global-polymer-modified-asphalt-market
Thermal Gap Fillers Market
The global thermal gap fillers market is projected to reach a value of approximately $1.2 billion in 2024, driven by the increasing demand for efficient thermal management solutions in electronics, automotive, and renewable energy sectors. For the forecast period of 2025 to 2034, the market is anticipated to exhibit strong growth, reaching an estimated value of $2.5 billion by 2034, translating to a Compound Annual Growth Rate (CAGR) of around 9% during this period.
https://exactitudeconsultancy.com/reports/64130/global-thermal-gap-fillers-market
EAA and EMAA Copolymer Market
The global EAA (Ethylene Acrylic Acid) and EMAA (Ethylene Methacrylic Acid) copolymer market is projected to reach approximately $1.8 billion in 2024, driven by increasing demand across various industries, including packaging, automotive, and adhesives. Forecasts suggest that this market will expand to around $3.5 billion by 2034, reflecting strong growth potential. This translates to a Compound Annual Growth Rate (CAGR) of about 7.0% over the period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63925/global-eaa-and-emaa-copolymer-market
Ammonium Acryloyldimethyltaurate VP Copolymer Market
The global market for Ammonium Acryloyldimethyltaurate, VP Copolymer was valued at approximately $200 million in 2024 and is projected to reach around $300 million by 2034. This corresponds to a Compound Annual Growth Rate (CAGR) of about 4.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63690/global-ammonium-acryloyldimethyltaurate-vp-copolymer-market
Polymer Dispersed Liquid Crystal PDLC Film Market
The global Polymer Dispersed Liquid Crystal (PDLC) film market is valued at approximately $1.2 billion in 2024 and is projected to expand significantly, reaching about $2.6 billion by 2034. This upward trajectory reflects a robust Compound Annual Growth Rate (CAGR) of around 8.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63685/global-polymer-dispersed-liquid-crystal-pdlc-film-market
2-Methyl-4-Phenylindene Market
The global market for 2-Methyl-4-Phenylindene is poised for significant growth, with a current market value estimated at approximately $120 million for 2024. Anticipated demand from sectors such as pharmaceuticals and specialty chemicals is projected to drive the market value to around $200 million by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63676/global-2-methyl-4-phenylindene-market
V-Cell Filter Market
The global V-Cell filter market is valued at approximately $2.7 billion, driven by increasing demand for efficient filtration systems across various sectors, including automotive, pharmaceuticals, and industrial applications. The market is projected to grow significantly, reaching an estimated value of $4.5 billion by 2034, representing a robust Compound Annual Growth Rate (CAGR) of around 5.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63459/global-v-cell-filter-market
Cyclopentene Market
The global cyclopentene market is projected to reach an estimated value of $195 million in 2024, driven by its applications in the production of resins, paints, and coatings. As industries increasingly focus on sustainable and high-performance materials, the market is expected to grow significantly, with a projected value reaching approximately $350 million by 2034. This forecast reflects a Compound Annual Growth Rate (CAGR) of around 6.2% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63355/global-cyclopentene-market
Food Packaging Barrier Film Market
The global food packaging barrier film market is valued at approximately $10 billion in 2024, with projections suggesting it will reach around $15.5 billion by 2034. This indicates a robust Compound Annual Growth Rate (CAGR) of 5.7% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63303/global-food-packaging-barrier-film-market
Smart Wristband Battery Market
The global smart wristband battery market is valued at approximately $4.2 billion, driven by the increasing adoption of wearable technology and heightened consumer interest in health and fitness monitoring. The market is projected to grow significantly, with an estimated value of $7.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 6.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/63260/global-smart-wristband-battery-market
CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.comSign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EBC Financial Group Launches over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients
EBC Financial Group Launches over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients

Yahoo

time13 minutes ago

  • Yahoo

EBC Financial Group Launches over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients

New ETF CFD Suite Delivers Global Market Themes and Real-Time Access & Flexibility LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC) has announced the launch of over 100 new U.S.-listed Exchange-Traded Fund (ETF) CFDs, expanding its multi-asset product suite and offering global client's deeper access to diversified, thematic trading opportunities. The rollout highlights EBC's ongoing commitment to delivering institutional-grade tools across asset classes, underpinned by flexibility, transparency, and efficiency. The new offering includes ETFs listed on the NYSE and NASDAQ, issued by leading asset managers such as Vanguard, iShares (BlackRock), and State Street Global Advisors. Thematic coverage spans a wide range of global macro and sectoral narratives. 'This expansion reflects our vision to bridge intelligent product design with market relevance,' said David Barrett, CEO of EBC Financial Group (UK) Ltd. 'The new products are a natural evolution for traders seeking targeted exposure with greater strategic flexibility. At EBC, we're building an ecosystem that empowers both precision and performance.' Thematic Access Meets Tactical Flexibility The additional ETF-linked instruments cover a variety of market exposures, including geographic allocations like the iShares MSCI Brazil ETF; fixed income-focused strategies such as the iShares iBoxx $ High Yield Corporate Bond Fund; and sector- or commodity-based indices including the United States Oil Fund LP and the Vanguard Health Care ETF. Other themes include dividend-related baskets, mid-cap equities, and style-based index tracking. These developments reflect wider industry interest in instruments that mirror trends in asset allocation without direct ownership of the underlying securities. Across many markets, sector-tilted and style-based index products are gaining relevance as participants seek flexible ways to align with global narratives. Historically, ETFs tracking specific economic cycles—such as commodity recoveries or emerging market rebounds—have demonstrated performance differentiation. The iShares MSCI Brazil ETF, for example, notably outperformed the S&P 500 during the post-pandemic recovery period in 2021, highlighting how thematic instruments can diverge from broad indices depending on market cycles. These additions serve as both stand-alone trade ideas and complementary instruments alongside EBC's existing product lineup, enabling advanced portfolio structuring and thematic trading. Smarter Exposure: Leverage, Shorting, and Cost Efficiency in One Product Compared to direct ETF investments, it presents several key advantages as traders benefit from a simplified cost structure, with no traditional fund management fees or broker commissions. The flexibility to take both long and short positions allows for strategic trading regardless of market direction, while the use of leverage enhances capital efficiency and return potential. These trades are executed in real time via EBC's recognised platforms, providing seamless access to market opportunities. During key market cycles, for example the post-pandemic V-shaped recovery of 2021—certain thematic ETFs, like the iShares MSCI Brazil ETF, significantly outperformed broader indices such as the S&P 500. Our portfolio enables traders to participate in similar trends, adapting quickly to shifting market dynamics with precision and speed. Getting Started These products can be accessed by registering on to begin simulated or live trading. About EBC Financial Group Founded in London's esteemed financial district, EBC Financial Group (EBC) is a global brand known for its expertise in financial brokerage and asset management. Through its regulated entities operating across major financial jurisdictions—including the UK, Australia, the Cayman Islands, Mauritius, and others—EBC enables retail, professional, and institutional investors to access a wide range of global markets and trading opportunities, including currencies, commodities, shares, and indices. Recognised with multiple awards, EBC is committed to upholding ethical standards and is licensed and regulated within the respective jurisdictions. EBC Financial Group (UK) Limited is regulated by the UK's Financial Conduct Authority (FCA); EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA); EBC Financial Group (Australia) Pty Ltd, and EBC Asset Management Pty Ltd are regulated by Australia's Securities and Investments Commission (ASIC); EBC Financial (MU) Ltd is authorised and regulated by the Financial Services Commission Mauritius (FSC). At the core of EBC are a team of industry veterans with over 40 years of experience in major financial institutions. Having navigated key economic cycles from the Plaza Accord and 2015 Swiss franc crisis to the market upheavals of the COVID-19 pandemic. We foster a culture where integrity, respect, and client asset security are paramount, ensuring that every investor relationship is handled with the utmost seriousness it deserves. As the Official Foreign Exchange Partner of FC Barcelona, EBC provides specialised services across Asia, LATAM, the Middle East, Africa, and Oceania. Through its partnership with United to Beat Malaria, the company contributes to global health initiatives. EBC also supports the 'What Economists Really Do' public engagement series by Oxford University's Department of Economics, helping to demystify economics and its application to major societal challenges, fostering greater public understanding and dialogue. Media Contact:Savitha RavindranGlobal Public Relations Michelle SiowBrand & Communications in to access your portfolio

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Hamilton Spectator

time17 minutes ago

  • Hamilton Spectator

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington. Details for the presentations are as follows: AXS-12 Title: ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in Narcolepsy Lead Author: Richard Bogan, MD, FCCP, FAASM, Associate Clinical Professor at the University of South Carolina School of Medicine in Columbia, SC Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-51 Poster Number: 405 Title: Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial Lead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY Oral Presentation Date and Time: Wednesday, June 11, 3:45 - 4 p.m. PT Oral Session: O-24 Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-51 Poster Number: 390 Title: Residual Symptom Burden in Patients with Narcolepsy Satisfied with Treatment: Subgroup Analysis from the CRESCENDO Survey Lead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY Oral Presentation Date and Time: Wednesday, June 11, 4 - 4:15 p.m. PT Oral Session: O-24 Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-51 Poster Number: 391 Solriamfetol Title: Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-50 Poster Number: 366 Title: Real-World Use of Solriamfetol for Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea in the US Lead Author: Yang Zhao, PhD, Axsome Therapeutics Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-50 Poster Number: 369 About AXS-12 AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator under development for the treatment of narcolepsy. AXS-12 is thought to modulate noradrenergic activity to promote maintain tone during wakefulness, and noradrenergic and cortical dopamine signaling to promote wakefulness and enhance cognition. AXS-12 has been granted U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of narcolepsy. AXS-12 is covered by issued patents providing protection to at least 2039. AXS-12 is an investigational drug product not approved by the FDA. About Solriamfetol Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT1A agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD). About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . Forward Looking Statements Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Mark Jacobson Chief Operating Officer (212) 332-3243 mjacobson@ Media: Darren Opland Director, Corporate Communications (929) 837-1065 dopland@

Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Yahoo

time23 minutes ago

  • Yahoo

Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral ischemic stroke WILLOWBROOK, Ill., June 11, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million equity investment from Sun Pharmaceutical Industries Limited (Reuters: Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies), one of the world's leading pharmaceutical companies. This strategic investment brings Sun Pharma's total commitment in Pharmazz to $40 million (including a previous $15 million equity investment). 'We believe sovateltide has the potential to redefine the treatment of ischemic stroke, which has not seen a new FDA approved non-thrombolytic therapy in over 30 years. This investment means we are now fully funded to complete our pivotal Phase 3 study and execute on our mission to make this first in class therapy available to stroke patients,' said Emeritus Prof. Anil Gulati, CEO and Founder of Pharmazz. 'We deeply value Sun Pharma's continued partnership, which strengthens our ability to bring our therapies to patients worldwide.' The new funding will provide Pharmazz with the capital required to complete the pivotal U.S. Phase 3 clinical trial of sovateltide (known as Tycamzzi® and Tyvalzi™ in international markets), its lead drug candidate for treating acute cerebral ischemic stroke. Dr. Neil Marwah, President of Pharmazz, added, 'This investment gives us the operational runway to execute a complex, multi-country clinical trial and scale the company responsibly as we prepare for a potential public offering. We are thrilled to strengthen our partnership with Sun Pharma, whose continued support reflects deep confidence in our platform and our ability to execute.' Phase 3 Trial of Sovateltide for Stroke Covered by Special Protocol Assessment Sovateltide is a first-in-class endothelin-B receptor agonist to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke patients. Pharmazz is initiating the Phase 3 RESPECT-ETB ( ID: NCT05691244) trial at 65 sites in the US, Germany, Spain, and the UK, designed to enroll 514 stroke patients. The primary endpoint is the proportion of patients demonstrating functional independence post-stroke, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after stroke onset. Commercially Approved in India: Early Validation from 60,000+ patients Sovateltide was approved in 2023 in India and marketed by Sun Pharma under the brand name Tyvalzi™, offering compelling proof of concept for global commercialization. In a randomized, placebo-controlled, multicenter clinical trial conducted in 158 cerebral ischemic stroke patients conducted in India, the product was shown to be well tolerated and effective in improving neurological outcomes when administered within 24 hours of stroke symptoms. Patients on Sovateltide were 22.7% more likely to achieve functional independence at 90 days (as measured by mRS score 0–2; p=0.0045) Sovateltide delivered a 17.1% higher rate of favorable National Institutes of Health Stroke Scale (NIHSS) scores (p=0.0024) The ordinal shift in mRS and NIHSS score between control and sovateltide groups was favorable towards sovateltide across the entire range. Results represent the first statistically significant clinical data in stroke in 30 years, since the introduction of alteplase (tPA) Over 60,000 patients treated to date since commercial launch in India Targeting a Multibillion-Dollar Market with a Broader Therapeutic Window Stroke remains one of the leading causes of disability and death globally, with over 7 million ischemic strokes annually. Today, fewer than 15% of patients receive approved interventions, largely due to their narrow treatment window and strict eligibility criteria. Sovateltide's 24-hour dosing window and broader eligibility could expand access—particularly for underserved populations—and position it as a major advance in acute stroke care. If successful in Phase 3 and subsequently approved, sovateltide has strong commercial potential and is expected to be a foundational product in the Pharmazz emerging neurology franchise. About Sovateltide Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide is unique because its action site is the neural progenitor cells. Sovateltide promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz, Inc. obtained marketing authorization for two of its first-in-class drug molecules, centhaquine and sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. In addition, the US Food and Drug Administration (FDA) has approved two phase III INDs for centhaquine as an agent for hypovolemic shock and sovateltide for cerebral ischemic stroke. Additional information may be found on the Company's website, About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. and global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit Disclaimer: Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors Kabir Marwah MediaShruti Gulati Tel +1 630 780 6087 Tel +1 630 780 6087 E mail E mail produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store